Ed Arce is a Managing Director of Equity Research at H.C. Wainwright with expertise in both the biopharmaceutical and the specialty pharmaceutical sectors. In particular, Mr. Arce’s research covers investment opportunities among hepatology, renal, infectious disease, gastrointestinal, endocrine, metabolic and select rare disease companies Mr. Arce has been involved in institutionally-focused healthcare research since 2005. Prior to joining H.C. Wainwright, Mr. Arce was a Senior Research Analyst at ROTH Capital Partners. Mr. Arce’s previous sell-side experience includes working for MLV & Co, Wedbush Securities, UBS Securities and First Albany Capital.
In 2017, Mr. Arce won the Thomson Reuters “No. 1 Top Stock Picker Award” in Biotechnology. Mr. Arce’s educational background includes a Master of Science in Finance (MSF) degree from Boston College, as well as both an MBA and a B.S. in Civil Engineering from Florida International University (FIU). Mr. Arce is also a Board-licensed Professional Engineer (P.E.) and a Level III Chartered Financial Analyst (CFA) candidate.
